Cost-of-illness of inflammatory bowel disease patients treated with anti-tumour necrosis factor: A French large single-centre experience.

Date publication

août 2019

Journal

United European gastroenterology journal

Auteurs

Membres identifiés du Cancéropôle Est :
Pr GUILLEMIN Francis , Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Lawton J, Achit H, Pouillon L, Boschetti E, Demore B, Matton T, Tournier C, Prodel M, Peyrin-Biroulet L, Guillemin F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/31428415

Résumé

No study has evaluated the direct annual costs of inflammatory bowel disease patients treated with anti-tumour necrosis factor therapy.

Mots clés

Anti-tumour necrosis factor therapy, Crohn’s disease, costs, inflammatory bowel disease, pharmacoeconomics, ulcerative colitis

Référence

United European Gastroenterol J. 2019 Aug;7(7):908-913